A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)
MK-4716-001
Phase 2 other active
Quick answer
A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001) for Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification) is a Phase 2 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)
- Phase
- Phase 2
- Modality
- other
- Status
- active